BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13%

Wider loss overshadows revenue. BridgeBio Pharma reported a loss of $1 per share for Q4 2025, wider than the expected loss of $0.62 per share by 50.6%. The biotechnology company’s net loss reached $192.9 million for the quarter. Despite the earnings miss, shares surged 13.2% to $74.32 on volume of 6.1 million shares, suggesting investors focused on other metrics beyond the bottom line.

Revenue climbs amid operational losses. The company generated $154.2 million in revenue for the quarter, with gross profit of $146.1 million against cost of revenue of just $8.1 million, yielding a gross margin of 94.7%. Operating loss totaled $128.4 million, while EBITDA came in at negative $143.0 million. Research and development expenses consumed $116.4 million, with selling, general and administrative costs adding another $158.1 million. The company burned $56.4 million in operating cash flow and $56.5 million in free cash flow during the quarter.